Aim: Patients with advanced cancer need information about end-of-life treatment options in order to make informed decisions. Clinicians vary in the frequency with which they initiate these discussions.
Patients and methods: As part of a long-term longitudinal study, patients with an expected 2-year survival of less than 50% who had advanced gastrointestinal or lung cancer or amyotrophic lateral sclerosis (ALS) were interviewed. Each patient’s medical record was reviewed at enrollment and at 3 months for evidence of the discussion of patient wishes concerning ventilator support, artificial nutrition and hydration (ANH), resuscitation (DNR) and hospice care. A Kaplan–Meier analysis was also performed and 2-year survival calculated.
Results: 60 cancer and 32 ALS patients were enrolled. ALS patients were more likely than cancer patients to have evidence of discussion about their wishes for ventilator support (31% vs 0%, p<0.001), ANH (38% vs 0%, p<0.001), DNR (25% vs 0%, p<0.001) and hospice care (22% vs 5%, p = 0.03). At 6 months, 91% of ALS patients were alive compared with 62% of cancer patients; at 2 years, 63% of ALS patients were alive compared with 23% of cancer patients (p<0.001).
Conclusions: Cancer patients were less likely than ALS patients to have had documented advanced care planning discussions despite worse survival. This may reflect perceptions that ALS has a more predictable course, that advanced cancer has a greater number of treatment options, or differing views about hope. Nevertheless, cancer patients may be less adequately prepared for end-of-life decision-making.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: None.
Funding: This study was funded by the National Institute of Nursing Research at the National Institutes of Health (1 R01 NR005224-01A1), by a grant from the Leslie R Samuels and Fan Fox Foundation (administered by the Partnership for Caring) and by the ALS Research Center of the Johns Hopkins University
Ethics approval: The study was approved by the institutional review boards at the Johns Hopkins Medical Institutions in Baltimore, Maryland and St Vincent’s Hospital Manhattan.
Read the full text or download the PDF:
Other content recommended for you
- Cognitive dysfunction in lower motor neuron disease: executive and memory deficits in progressive muscular atrophy
- Study on sleep-wake disorders in patients with genetic and non-genetic amyotrophic lateral sclerosis
- Pathophysiological insights into ALS with C9ORF72 expansions
- Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis
- Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS
- Coping, mood and health-related quality of life: a cross-sectional study in Chinese patients with advanced lung cancer
- Differential corticospinal tract degeneration in homozygous ‘D90A’ SOD-1 ALS and sporadic ALS
- Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan
- Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice
- Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000